Ono 1301

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525784

CAS#: 176391-41-6

Description: Ono 1301 is a non-prostanoid prostaglandin I2 mimetic coumpound with inhibitory activity against thromboxane A2 synthase. It is also a novel long-acting prostacyclin agonist loaded in PLGA microspheres prepared using different molecular weights of PLGA. ONO-1301 suppresses pancreatic fibrosis in the DBTC-induced CP model by inhibiting monocyte activity not only with induction of HGF but also by ONO-1301 itself. It also works through promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling.

Chemical Structure

Ono 1301
CAS# 176391-41-6

Theoretical Analysis

MedKoo Cat#: 525784
Name: Ono 1301
CAS#: 176391-41-6
Chemical Formula: C27H26N2O4
Exact Mass: 442.1893
Molecular Weight: 442.5063
Elemental Analysis: C, 73.28; H, 5.92; N, 6.33; O, 14.46

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ono1301; Ono-1301; Ono 1301

IUPAC/Chemical Name: (Z)-2-((6-methyl-5-(2-(((phenyl(pyridin-3-yl)methylene)amino)oxy)ethyl)-7,8-dihydronaphthalen-1-yl)oxy)acetic acid


InChi Code: InChI=1S/C27H26N2O4/c1-19-12-13-24-23(10-5-11-25(24)32-18-26(30)31)22(19)14-16-33-29-27(20-7-3-2-4-8-20)21-9-6-15-28-17-21/h2-11,15,17H,12-14,16,18H2,1H3,(H,30,31)/b29-27-


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 442.5063 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Kashiwagi H, Yuhki K, Kojima F, Kumei S, Takahata O, Sakai Y, Narumiya S, Ushikubi F. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015 May;353(2):269-78. doi: 10.1124/jpet.115.222612. Epub 2015 Mar 4. PubMed PMID: 25740898.
2: Watatani H, Yamasaki H, Maeshima Y, Nasu T, Hinamoto N, Ujike H, Sugiyama H, Sakai Y, Tanabe K, Makino H. ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells. Acta Med Okayama. 2015;69(1):1-15. PubMed PMID: 25703166.
3: Hazekawa M, Morihata K, Yoshida M, Sakai Y, Uchida T. The angiogenic effect of ONO-1301, a novel long-acting prostacyclin agonist loaded in PLGA microspheres prepared using different molecular weights of PLGA, in a murine sponge model. Drug Dev Ind Pharm. 2014 Nov;40(11):1435-42. doi: 10.3109/03639045.2013.828220. Epub 2013 Aug 13. PubMed PMID: 23937583.
4: Niina Y, Ito T, Oono T, Nakamura T, Fujimori N, Igarashi H, Sakai Y, Takayanagi R. A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology. 2014 May-Jun;14(3):201-10. doi: 10.1016/j.pan.2014.02.009. Epub 2014 Mar 15. PubMed PMID: 24854616.
5: Uchida T, Hazekawa M, Yoshida M, Matsumoto K, Sakai Y. Novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling. J Pharmacol Sci. 2013;123(4):392-401. Epub 2013 Nov 30. PubMed PMID: 24292413.
6: Hirata Y, Kurobe H, Uematsu E, Yagi S, Soeki T, Yamada H, Fukuda D, Shimabukuro M, Nakayama M, Matsumoto K, Sakai Y, Kitagawa T, Sata M. Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol. 2013 Jan 15;699(1-3):81-7. doi: 10.1016/j.ejphar.2012.11.045. Epub 2012 Dec 5. PubMed PMID: 23219794.
7: Uchida T, Hazekawa M, Morisaki T, Yoshida M, Sakai Y. Effect of antioxidants on the stability of ONO-1301, a novel long-acting prostacyclin agonist, loaded in PLGA microspheres. J Microencapsul. 2013;30(3):245-56. doi: 10.3109/02652048.2012.720721. Epub 2012 Oct 25. PubMed PMID: 23094609.
8: Nasu T, Kinomura M, Tanabe K, Yamasaki H, Htay SL, Saito D, Hinamoto N, Watatani H, Ujike H, Suzuki Y, Sugaya T, Sugiyama H, Sakai Y, Matsumoto K, Maeshima Y, Makino H. Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol Renal Physiol. 2012 Jun 15;302(12):F1616-29. doi: 10.1152/ajprenal.00538.2011. Epub 2012 Mar 14. PubMed PMID: 22419696.
9: Hirata Y, Shimabukuro M, Uematsu E, Soeki T, Yamada H, Sakai Y, Nakayama M, Matsumoto K, Igarashi T, Sata M. A synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, ONO-1301, protects myocardium from ischemia/reperfusion injury. Eur J Pharmacol. 2012 Jan 15;674(2-3):352-8. doi: 10.1016/j.ejphar.2011.10.038. Epub 2011 Nov 9. PubMed PMID: 22094066.
10: Hazekawa M, Sakai Y, Yoshida M, Haraguchi T, Uchida T. Single injection of ONO-1301-loaded PLGA microspheres directly after ischaemia reduces ischaemic damage in rats subjected to middle cerebral artery occlusion. J Pharm Pharmacol. 2012 Mar;64(3):353-9. doi: 10.1111/j.2042-7158.2011.01416.x. Epub 2011 Dec 7. PubMed PMID: 22309267.
11: Hazekawa M, Sakai Y, Yoshida M, Haraguchi T, Uchida T. The effect of treatment with a sustained-release prostacyclin analogue (ONO-1301-loaded PLGA microsphere) on short-term memory impairment in rats with transient global cerebral ischemia. J Microencapsul. 2012;29(3):211-8. doi: 10.3109/02652048.2011.622054. Epub 2012 Feb 24. PubMed PMID: 22360765.
12: Hazekawa M, Sakai Y, Yoshida M, Haraguchi T, Morisaki T, Uchida T. Preparation of ONO-1301-loaded poly(lactide-co-glycolide) microspheres and their effect on nerve conduction velocity. J Pharm Pharmacol. 2011 Mar;63(3):362-8. doi: 10.1111/j.2042-7158.2010.01237.x. Epub 2011 Feb 8. PubMed PMID: 21749383.
13: Yamasaki H, Maeshima Y, Nasu T, Saito D, Tanabe K, Hirokoshi-Kawahara K, Sugiyama H, Sakai Y, Makino H. Intermittent administration of a sustained-release prostacyclin analog ONO-1301 ameliorates renal alterations in a rat type 1 diabetes model. Prostaglandins Leukot Essent Fatty Acids. 2011 Mar-Apr;84(3-4):99-107. doi: 10.1016/j.plefa.2010.11.005. Epub 2010 Dec 21. PubMed PMID: 21177088.
14: Hirata Y, Soeki T, Akaike M, Sakai Y, Igarashi T, Sata M. Synthetic prostacycline agonist, ONO-1301, ameliorates left ventricular dysfunction and cardiac fibrosis in cardiomyopathic hamsters. Biomed Pharmacother. 2009 Dec;63(10):781-6. doi: 10.1016/j.biopha.2009.09.003. Epub 2009 Oct 13. PubMed PMID: 19906506.
15: Minamoto K. [Beneficial effect of a stable PGI2 analogue (ONO-1301) on prostanoid release after reperfusion in canine left single lung allotransplantation model]. Nihon Kyobu Geka Gakkai Zasshi. 1997 Dec;45(12):1931-42. Japanese. PubMed PMID: 9455104.
16: Hayashi K, Nagamatsu T, Oka T, Suzuki Y. Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. Jpn J Pharmacol. 1997 Jan;73(1):73-82. PubMed PMID: 9032136.
17: Nakamura K, Sata M, Iwata H, Sakai Y, Hirata Y, Kugiyama K, Nagai R. A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin Sci (Lond). 2007 Jun;112(12):607-16. PubMed PMID: 17263691.
18: Murakami S, Nagaya N, Itoh T, Kataoka M, Iwase T, Horio T, Miyahara Y, Sakai Y, Kangawa K, Kimura H. Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2006 Jan;290(1):L59-65. Epub 2005 Sep 9. PubMed PMID: 16155090.